Tremor, Dystonia & Chorea Pharm

Essential tremor, dystonia, and other movement disorders comprise a heterogeneous group of conditions with distinct pharmacologic approaches. Essential tremor responds to specific β-blockers, primidone, topiramate, and increasingly to focused ultrasound or DBS. Dystonias respond variably to anticholinergics, dopaminergic therapy (in DOPA-responsive dystonia), botulinum toxin, and deep brain stimulation. Other tremor syndromes (orthostatic, cerebellar, dystonic) and movement disorders (functional, paroxysmal) require tailored approaches. This page covers tremor, dystonia, and related movement disorders.

Essential Tremor (ET)

First-Line Pharmacotherapy

  • Propranolol: 60-320 mg/day; non-selective β-blocker; most effective single agent; mechanism via β2 (not central β).
  • Primidone: 50-750 mg/day; barbiturate-related ASM; comparable efficacy to propranolol.
  • Combination of propranolol + primidone often superior to either alone.

Second-Line

  • Topiramate: 200-400 mg/day; cognitive trade-off.
  • Gabapentin: 1200-3600 mg/day.
  • Atenolol, sotalol, nadolol: alternative β-blockers.
  • Benzodiazepines (clonazepam, alprazolam): adjunctive for specific situations.

Refractory ET

  • Vim DBS: very effective; unilateral or bilateral.
  • MR-guided focused ultrasound thalamotomy (MRgFUS): incisionless alternative; effective; rapid; one-time procedure.
  • Vim radiofrequency thalamotomy: historical alternative.

ET vs PD Differentiation

  • ET: action/postural tremor predominant; no rigidity, bradykinesia.
  • PD: rest tremor predominant; rigidity, bradykinesia.
  • DAT scan can help differentiate.

Dystonia

Generalized Dystonia

  • DOPA-responsive dystonia (Segawa): ALWAYS try levodopa first — dramatic response possible; lifelong treatment.
  • Trihexyphenidyl: high-dose for early-onset (DYT1).
  • Baclofen: oral or intrathecal.
  • Tetrabenazine, deutetrabenazine, valbenazine: for refractory; especially DYT1.
  • Benzodiazepines (clonazepam): adjunct.
  • GPi DBS: highly effective for refractory generalized dystonia.

Focal Dystonias

  • Botulinum toxin: first-line for most focal dystonias (cervical, blepharospasm, hemifacial, oromandibular, laryngeal/spasmodic dysphonia, limb).
  • Type A: onabotulinumtoxinA (Botox), incobotulinumtoxinA (Xeomin), abobotulinumtoxinA (Dysport).
  • Type B: rimabotulinumtoxinB (Myobloc) — useful when type A resistance.
  • Treatment every 3-4 months; titrated by response.

Cervical Dystonia (Spasmodic Torticollis)

  • Botulinum toxin to involved muscles.
  • Trihexyphenidyl, baclofen, clonazepam adjunctive.
  • Deep brain stimulation if refractory.

Blepharospasm

  • Botulinum toxin to orbicularis oculi.
  • Apraxia of eyelid opening: harder to treat; pretarsal injections.

Writer’s Cramp / Task-Specific Dystonias

  • Botulinum toxin to involved forearm muscles.
  • Trihexyphenidyl high-dose.
  • Surgical retraining therapy.

Drug-Induced Dystonia

  • Acute: most common with D2 antagonists; benadryl IV/IM (50 mg) or benztropine IV/IM (1-2 mg) rapidly effective.
  • Tardive dystonia: long-term D2 antagonist exposure; VMAT2 inhibitors.

Huntington Disease

Chorea

  • Tetrabenazine (Xenazine): VMAT2 inhibitor; reduces chorea; depression risk; sedation.
  • Deutetrabenazine (Austedo): deuterated; longer half-life; less frequent dosing; better tolerated.
  • Valbenazine (Ingrezza): not FDA-approved for HD but used.
  • Risperidone, olanzapine: dual chorea + behavioral.

Behavioral / Psychiatric

  • SSRIs for depression.
  • Atypical antipsychotics for psychosis, aggression.
  • Mood stabilizers.

Cognitive

  • No effective pharmacotherapy.
  • Manage contributors (sleep, mood, comorbidities).

Disease-Modifying (Investigational)

  • Tominersen (anti-huntingtin antisense oligonucleotide): trial discontinued for efficacy/safety concerns.
  • Multiple emerging gene-targeted therapies in development.

Tic Disorders / Tourette Syndrome

Behavioral Therapy First

  • Comprehensive Behavioral Intervention for Tics (CBIT): first-line; effective.

Pharmacologic

  • Guanfacine, clonidine: α2 agonists; first-line pharmacotherapy.
  • Aripiprazole: increasingly used; balanced D2 partial agonism.
  • Risperidone: effective but tardive dyskinesia risk.
  • Haloperidol, pimozide: historical; tardive risk.
  • Topiramate: alternative.
  • Botulinum toxin: focal motor or vocal tics.
  • DBS: refractory cases (research/specialized).

Tardive Dyskinesia

  • Valbenazine (Ingrezza): VMAT2 inhibitor; FDA-approved for TD.
  • Deutetrabenazine (Austedo): VMAT2; FDA-approved for TD.
  • Reduce or eliminate offending D2 antagonist when possible.
  • Avoid anticholinergics (may worsen TD).
  • Vitamin E: limited evidence.
  • Tetrabenazine: alternative.

Restless Legs Syndrome (RLS)

  • Iron replacement: if ferritin <75-100 (or transferrin saturation low); often dramatic.
  • α2δ ligands (gabapentin, pregabalin): increasingly first-line; lower augmentation risk than dopamine.
  • Dopamine agonists (pramipexole, ropinirole, rotigotine): traditional first-line; augmentation risk.
  • Augmentation: paradoxical worsening with chronic dopamine; switching strategies.
  • Opioids: severe refractory cases.

Functional Movement Disorders

  • Increasingly recognized; psychotherapy, physical therapy mainstays.
  • SSRIs/SNRIs may help comorbid mood.
  • Avoid unnecessary anti-movement medications.
  • Clinical certainty important to avoid misdiagnosis as functional.

Paroxysmal Dyskinesias

  • Paroxysmal kinesigenic dyskinesia (PKD): triggered by movement; carbamazepine highly effective.
  • Paroxysmal non-kinesigenic dyskinesia (PNKD): triggered by stress, alcohol; harder to treat; clonazepam, acetazolamide.
  • Paroxysmal exercise-induced dyskinesia (PED): triggered by sustained exercise; consider GLUT1 deficiency, ketogenic diet.
  • Familial forms often well-treated with appropriate ASM.

Wilson Disease (Movement Components)

  • D-penicillamine, trientine: chelation.
  • Zinc: copper binding in gut.
  • Tetrathiomolybdate: investigational.
  • Always consider in young adults with new tremor, dystonia, or parkinsonism + hepatic/psychiatric features.

Ataxia Pharmacotherapy

  • Most genetic ataxias: limited pharmacotherapy; physical therapy mainstay.
  • Episodic ataxia type 2: acetazolamide effective.
  • Riluzole: some evidence in some ataxias (controversial).
  • Coenzyme Q10: empirical in coenzyme Q10 deficiency.
  • Idebenone: Friedreich ataxia (limited efficacy).
  • Omaveloxolone: Friedreich ataxia (FDA-approved 2023).
  • Levodopa: parkinsonism component of MSA.

MSA Pharmacotherapy

  • Parkinsonian: levodopa often poor response; trial dose.
  • Orthostasis: fludrocortisone, midodrine, droxidopa, pyridostigmine.
  • Cerebellar: PT.
  • Bladder: anticholinergics or mirabegron; catheterization.
  • REM sleep behavior disorder: clonazepam, melatonin.

PSP Pharmacotherapy

  • Levodopa: limited response.
  • Amantadine: some benefit.
  • Treat falls aggressively (highest priority).
  • Botulinum toxin for axial dystonia, eyelid retraction.

🔍 Did You Know?

DOPA-responsive dystonia (Segawa syndrome) is one of the most rewarding diagnoses in pediatric and adult neurology — a condition where the right treatment can produce dramatic, life-changing improvement and where misdiagnosis can mean decades of unnecessary disability. The condition results from autosomal-recessive mutations in GTP cyclohydrolase 1 (GCH1) gene, which reduces tetrahydrobiopterin synthesis and consequently dopamine production. The clinical presentation typically includes early-onset (often <10 years) lower-limb dystonia, often with diurnal variation (worse in evening), sometimes mistaken for cerebral palsy or muscular dystrophy. Children may be wheelchair-bound or unable to walk. The treatment? Low-dose levodopa (often just 100-200 mg daily) can produce dramatic, near-complete reversal of dystonia within days to weeks, and the response is sustained throughout life without significant motor fluctuations or dyskinesias (unlike PD). For practicing neurologists, the clinical pearl: any childhood-onset dystonia deserves a levodopa trial, particularly if there is diurnal variation or family history. The same principle extends to adults: some adults with previously misdiagnosed “primary dystonia” turn out to have DOPA-responsive dystonia and respond beautifully to levodopa. The lesson generalizes: specific genetic causes of neurologic disease can have specific, targeted treatments, and clinical recognition pays off enormously when the response is so dramatic.

Pitfalls and Pearls

  • ET first-line: propranolol, primidone; combination often best.
  • ET refractory: Vim DBS or MR-guided focused ultrasound thalamotomy.
  • Dystonia + childhood/diurnal pattern: trial levodopa (DOPA-responsive dystonia).
  • Focal dystonia: botulinum toxin first-line.
  • Generalized dystonia: trihexyphenidyl, baclofen, GPi DBS.
  • Cervical dystonia: botulinum toxin to involved muscles.
  • HD chorea: tetrabenazine, deutetrabenazine, valbenazine.
  • HD depression: SSRIs.
  • Tourette first-line: behavioral (CBIT); guanfacine, clonidine, aripiprazole.
  • Tardive dyskinesia: valbenazine, deutetrabenazine.
  • RLS: iron first; α2δ ligands or dopamine agonists.
  • RLS augmentation: paradoxical dopamine worsening.
  • PKD (paroxysmal kinesigenic dyskinesia): carbamazepine highly effective.
  • Wilson disease: always consider in young adult with new movement disorder + psychiatric/hepatic.
  • Episodic ataxia type 2: acetazolamide.
  • MSA orthostasis: droxidopa effective; can have supine hypertension.

References

  1. Bhatia KP, Bain P, Bajaj N, et al. Consensus Statement on the classification of tremors. Mov Disord. 2018;33(1):75-87.
  2. Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28(7):863-873.
  3. Lyons MK, Rezai AR, Lozano AM. Deep brain stimulation in essential tremor and dystonia. Curr Treat Options Neurol. 2020;22(11):31.
  4. Reed XP, Maraganore DM. Essential tremor. Postgrad Med J. 2021;97(1148):369-374.
  5. Coffey RJ, Edgar TS, Francisco GE, et al. Abrupt withdrawal from intrathecal baclofen. Arch Phys Med Rehabil. 2002;83(6):735-741.
  6. Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease. Sleep Med. 2016;21:1-11.